A panelist discusses how the choice between microformulation abiraterone and off-label low-dose regimens is often dictated by cost and insurance coverage rather than purely clinical considerations.

Mina M. Fam, MD, discusses some of the common misconceptions that patients have when seeking testosterone replacement therapy.

The United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for nogapendekin alfa inbakicept-pmln (NAI, Anktiva) in combination with BCG for the ...

The FDA has granted fast track designation for TRE-515 in combination with 177 Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan; Pluvicto) for the treatment of metastatic castration-resistant ...

Axena Health's collaboration with Mayo Clinic enriches the Leva app with educational content on urinary incontinence and bladder health. The Leva Pelvic Health System, FDA-cleared, offers real-time ...

The FDA and European Medicines Agency (EMA) have granted authorization for a confirmatory phase 3 trial that will evaluate masitinib in metastatic castrate-resistant prostate cancer (mCRPC), AB ...

Treatment of non-metastatic hormone-sensitive prostate cancer (nmHSPC) with enzalutamide (Xtandi) in combination with leuprolide acetate was associated with significantly improved overall survival (OS ...

Benjamin M. Brucker, MD, outlines considerations surrounding pre-procedure urinalysis, prophylactic periprocedural antibiotics, and optimal dosing regimens for onabotA administration.

Anne K. Schuckman, MD, discusses some of the current challenges in delivering optimal care for patients with non–muscle invasive bladder cancer.

On June 18, 2025, the FDA granted clearance to Neuspera Medical’s integrated sacral neuromodulation (iSNM) system for the treatment of patients with urinary urge incontinence. 1 In this video, Andrea ...

A recent study in JAMA Network Open found that although trimodal therapy (TMT) improved quality of life for patients with muscle-invasive bladder cancer, it was not as cost-effective as radical ...

Johnson & Johnson has submitted an application to the European Medicine’s Agency (EMA) seeking an expanded indication for niraparib and abiraterone acetate (Akeega) with prednisone or prednisolone to ...